Last reviewed · How we verify
Insulin Aspart 70
Insulin Aspart 70 is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels.
Insulin Aspart 70 is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Aspart 70 |
|---|---|
| Also known as | Novomix 70 |
| Sponsor | Medical University of Graz |
| Drug class | Insulin analog (biphasic) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin Aspart is a recombinant human insulin analog with a faster onset and shorter duration of action than regular human insulin. The '70' designation indicates this is a biphasic formulation containing 70% intermediate-acting insulin (NPH) and 30% rapid-acting insulin aspart. It mimics the body's natural insulin secretion pattern by providing both basal and mealtime glucose control.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes. (NA)
- Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus (PHASE3)
- Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy (PHASE4)
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study (PHASE4)
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Aspart 70 CI brief — competitive landscape report
- Insulin Aspart 70 updates RSS · CI watch RSS
- Medical University of Graz portfolio CI